Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>CICC Elevates INNOVENT BIO's TP to $66; 1Q25 Rev. in Line
Recommend 2 Positive 7 Negative 2 |
||||
|
||||
|
INNOVENT BIO (01801.HK)'s 1Q25 product revenue maintained a YoY growth of over 40% to more than RMB2.4 billion, in line with expectations, according to a CICC report. In addition, the group forecasted that it will present several blockbuster data sets at the 2025 ASCO Annual Meeting, including seven oral presentations. Given INNOVENT BIO's commitment to continue enriching its portfolio of commercialized products, CICC estimated its 2025 revenue to sustain the strong growth momentum seen in 1Q. The broker kept its 2025-26 net profit forecasts for the group at RMB472 million and RMB1.298 billion, while reiterating the Outperform rating. CICC also raised its target price for INNOVENT BIO by 12.2% to $66, after taking into account the maturity of the group's IBI363 PoC data and the progress of its ADC pipeline, which are expected to unlock more room for global commercialization. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
